Cerevasc Inc. has treated its first U.S. patient using an investigational device intended for patients suffering from hydrocephalus, one of the most common neurological conditions worldwide. Boston-based Cerevasc’s Eshunt system is being taken through its paces during a clinical study in Buenos Aires, Argentina and is aimed at replacing a half-century-old neurosurgical procedure associated with frequent failure, infection risk and high costs.